Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo
Metrics: PDF 2045 views | HTML 1717 views | ?
Hongbiao Huang1,*, Yuning Liao1,*, Ningning Liu1,2, Xianliang Hua1, Jianyu Cai1, Changshan Yang1, Huidan Long1, Chong Zhao1, Xin Chen1, Xiaoying Lan1, Dan Zang1, Jinjie Wu1, Xiaofen Li1, Xianping Shi1, Xuejun Wang1,3, Jinbao Liu1
1State Key Laboratory of Respiratory Disease, Protein Modification and Degradation Laboratory, Department of Pathophysiology, Guangzhou Medical University, Guangdong 511436, People’s Republic of China
2Guangzhou Research Institute of Cardiovascular Disease, The Second Affiliated Hospital, Guangzhou Medical University, Guangdong 510260, People’s Republic of China
3Division of Basic Biomedical Sciences, Sanford School of Medicine of the University of South Dakota, Vermillion, South Dakota 57069, USA
*These authors contributed equally to this work
Hongbiao Huang, e-mail: email@example.com
Jinbao Liu, e-mail: firstname.lastname@example.org
Keywords: auranofin, deubiquitinase inhibitor, disulfiram, anticancer strategy
Received: August 10, 2015 Accepted: November 16, 2015 Published: November 28, 2015
Inhibition of proteasome-associated deubiquitinases (DUBs) is emerging as a novel strategy for cancer therapy. It was recently reported that auranofin (Aur), a gold (I)-containing compound used clinically to treat rheumatoid arthritis, is a proteasome-associated DUB inhibitor. Disulfiram (DSF), an inhibitor of aldehyde dehydrogenase, is currently in clinical use for treating alcoholism. Recent studies have indicated that DSF can also act as an antitumor agent. We investigated the effect of combining DSF and Aur on apoptosis induction and tumor growth in hepatoma cancer cells. Here we report that (i) the combined treatment of Aur and DSF results in synergistic cytotoxicity to hepatoma cells in vitro and in vivo; (ii) Aur and DSF in combination induces caspase activation, endoplasmic reticulum (ER) stress, and reactive oxygen species (ROS) production; (iii) pan-caspase inhibitor z-VAD-FMK could efficiently block apoptosis but not proteasome inhibition induced by Aur and DSF combined treatment, and ROS is not required for Aur+DSF to induce apoptosis. Collectively, we demonstrate a model of synergism between DSF and proteasome-associated DUB inhibitor Aur in the induction of apoptosis in hepatoma cancer cells, identifying a potential novel anticancer strategy for clinical use in the future.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.